Study Overview: This study is testing two treatments for multiple myeloma, a type of blood cancer. In one group, patients will receive four medicines: Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (together called DVRd), followed by a new treatment called Ciltacabtagene Autoleucel, which is a special type of cell therapy. In the other group, patients will receive the same four medicines (DVRd) and then undergo a procedure called Autologous Stem Cell Transplant (ASCT), where their own stem cells are used to help fight the cancer. The goal is to see which treatment helps patients live longer without their cancer getting worse. Key Points:

• The study will involve about 750 participants across two groups.
• Participants must have newly diagnosed multiple myeloma and be eligible for high-dose therapy and ASCT.
• Patients will not have received certain previous treatments or vaccines recently.

Eligibility: Participants need to have specific blood test results and overall good health. Those who have already undergone similar treatments or have had certain health issues might not qualify.